Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2014. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility regarding their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary Shares by various directors and executives on July 10, 2014. These acquisitions were executed at a price of 1,561.76 pence per share through the reinvestment of dividends under the GlaxoSmithKline ShareReward Plan. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of 1,561.76 pence per Ordinary Share on July 10, 2014.
- Confirm the total number of shares acquired by each listed director through the ShareReward Plan dividend reinvestment.
- Note that this filing does not reflect the company's broader financial results for the period.